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Abstract 
Hepatitis C virus (HCV)-related liver disease is a 
significant cause of morbidity and mortality in patients 
with end-stage renal disease (ESRD) who is treated with 
dialysis or kidney transplantation (KT). The survival rate 
for HCV-infected renal transplant recipients is better 
than that for HCV-infected hemodialysis patients on 
transplant waiting lists. Early diagnosis and treatment 
HCV infection prior to KT prevents complications post-
transplantation and reduces mortality. In addition to 
screening for anti-HCV antibodies and detecting HCV 
RNA, percutaneous liver biopsy is particularly valuable 
for assessing the stage of liver damage in HCV-infected 
patients, because the stage of fibrosis is important 
determining optimal treatment for HCV. Studies have 
been demonstrated that with conventional interferon 
(IFN) monotherapy or pegylated IFN monotherapy are 
similar efficacy and safety in HCV-infected hemodialysis 
patients. Sustained viral responses (SVRs) with these 
monotherapies have ranged approximately 30% to 
40%. Limited reports support the use of IFN and 
ribavirin combination therapy as antiviral treatment for 
ESRD patients or patients on hemodialysis. Ribavirin 
can be started at low dose and careful monitoring for 
side effects. Patients that show SVR after treatment are 
strong candidates for KT. It is also generally accepted 
that ESRD patients with decompensated cirrhosis and 
portal hypertension should be referred to the liver 
transplant team for consideration of combined liver-KT. 
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Core tip: Hepatitis C virus (HCV)-related liver disease is 
a significant cause of morbidity and mortality in patients 
with end-stage renal disease who are treated with dialysis 
or KT. Early diagnosis and treatment of HCV infection 
prior kidney transplantation (KT) prevent complications 
after transplantation and reduces mortality. Issues with 
current mode HCV therapy include lack of tolerability and 
suboptimal response rates.
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Hepatitis C infection in hemodialysis patients: A review
is a significant cause of morbidity and mortality in 
hemodialysis (HD) patients and kidney transplant 
recipients. In developed countries, the prevalence of 
anti-HCV seropositivity among patients on maintenance 
HD ranges between 5% and 60%. Patients on HD 
are at high risk for HCV, with frequency of infection 
several times higher than that in non-uremic patients[1]. 
The spread of HCV in HD units is declining, but the 
prevalence of HCV in HD patients remains high[1].
Several observational studies have demonstrated 
a significant and independent relationship between 
anti-HCV seropositive status and lower survival rate 
in patients with end-stage renal disease (ESRD). The 
two major complications of HCV-related chronic liver 
disease are cirrhosis and hepatocellular carcinoma, and 
these are suspected causes of higher mortality among 
HCV-positive patients.
Management of HCV-positive ESRD patients is 
complicated. There are unknowns related to prevention 
of HCV spread in dialysis units, anti-viral therapy in 
dialysis patients, and effects of HCV infection after renal 
transplantation. A wide range of studies have been 
published on HCV in ESRD patients, but clinical evidence 
is lacking with respect to most of the important issues, 
and most existing evidence is from uncontrolled clinical 
trials or retrospective surveys[2-4].
EPIDEMIOLOGY OF HCV INFECTION
Serologic testing has clearly demonstrated that HCV 
infection is highly prevalent among ESRD patients and is 
a serious cause of increased morbidity and mortality in 
this group. Failures of HCV screening, excessive exposure 
to blood and blood products, nosocomial transmission of 
HCV in HD units, and long dialysis duration are the main 
determinants of increased risk of HCV infection in the 
HD patient group[5]. The worldwide prevalence of HCV 
infection among HD patients varies widely, with estimates 
ranging from 5% to approximately 60% depending on 
geographic location[6-9]. In 2002, the prevalence of HCV 
infection across HD centers of the United States was 
approximately 8%, nearly five times greater than that 
of the general population in that country[10,11]. In some 
European dialysis centers, the yearly incidence of HCV 
infection reportedly ranges from 0.4% to 16.0%[12]. In 
2011, the Turkish Society of Nephrology documented 
7.9% anti-HCV seropositivity and 1.7% HCV-RNA 
seropositivity among Turkish HD patients[13]. Introduction 
of stricter blood bank screening rules, widespread use 
of erythropoiesis-stimulating agents instead of blood 
transfusions, and stronger adherence to infection control 
practices in dialysis units have reduced the prevalence of 
HCV infection in the HD patient group[14]. For example, 
Spain observed a decline from 24% in 1992 to 9.2% in 
2002[15]. Anti-HCV prevalence among patients on chronic 
HD in the United States decreased from 10.4% in 1995 
to 7.8% (i.e., 164632 Americans) in 2002[2]. A recent 
multicenter survey revealed that prevalence of anti-HCV 
positivity for a Belgian cohort of HD patients (n = 1710) 
dropped steadily from 13.5% in 1991 to 6.8% in 2000, 
and the same survey revealed significant drops in many 
other countries including France (42% to 30%), Italy 
(27% to 16%), and Sweden (16% to 9%)[2].
IMPACT OF HCV ON SURVIVAL
One study that involved the database of more than 
13000 HD patients in the United States revealed that 
HCV infection was more strongly associated with all 
causes of mortality than with HCV-negative status[16]. 
Lee et al[17] identified HCV infection as an independent 
risk factor for the transition from chronic kidney disease 
to ESRD. A meta-analysis by Fabrizi et al[18] revealed that 
HD can negatively modify the course of HCV infection. 
The authors found that the estimated relative risk of 
liver-related mortality in anti-HCV-positive patients on 
HD was 1.57 times (95%CI: 1.33-1.86; P < 0.001) than 
that observed for anti-HCV-negative counterparts. The 
authors concluded that, in HD patients, the presence 
of anti-HCV antibodies is an independent risk factor 
for death, because of increased risk of cirrhosis and 
hepatocellular carcinoma. Other research has shown 
that kidney transplantation (KT) improves the long-
term survival of ESRD patients with HCV infection[19,20]. 
While there is considerable evidence that HCV infection 
threatens the success of KT, the survival of HCV-
infected renal transplant recipients is better than that 
for HCV-infected HD patients who are on transplant 
waiting lists[21]. This survival advantage may reflect 
systemic effects of well-functioning renal allografts that 
is clearing uremic toxins, and may also reflect reduced 
inflammatory responses and oxidative stress. HCV-
related deterioration of renal transplant recipients may 
be linked to the immunosuppressive treatment that is 
required after KT. This can result in flares of HCV infection 
and can increase liver- and kidney-related morbidity and 
mortality from conditions such as cirrhosis, hepatocellular 
carcinoma, transplant glomerulopathy, and graft 
dysfunction[22].
PREVENTION OF HCV TRANSMISSION
Health care procedures related to nosocomial infections, 
unsafe drug injection practices, and blood transfusions 
are key factors in HCV transmission. In HD facilities, 
the most common lapses of healthcare quality are 
contamination of dialysis systems, inadequate disinfection 
and cleaning of environmental surfaces, improper 
contact of health care staff with equipment and patients, 
and mishandling of parenteral medications[23,24]. The 
guidelines for preventing HCV infection in HD settings 
recommend fundamental infection control practices, and 
routine screening of HD patients for HCV. Isolating-HCV-
infected patients or using dedicated machines for such 
patients are not advocated, except as necessary during 
local outbreaks[12,24].
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DIAGNOSIS OF HCV INFECTION IN 
PATIENTS WITH ESRD
Infection with HCV normally leads to increased serum 
alanine aminotransferase (ALT), and laboratory blood 
testing for ALT is used to screen for liver disease in the 
general population. However, this test has weak diagnostic 
value in ESRD patients because ALT tends to be below 
reference range in this patient group. The potential causes 
of this are vitamin B6 deficiency, presence of uremic 
toxins, or presence of blood components that absorb 
ultraviolet light[25]. To detect HCV viremia in HD patients, 
new thresholds for serum ALT have been proposed that 
are less than half (approximately 0.4 to 0.45 times) the 
conventional threshold[26]. Serial testing of serum ALT 
level might be valuable for monitoring patients on HD 
with known HCV infection.
Enzyme-linked immunoassays (EIAs) are commonly 
used to detect HCV antibodies. Third-generation EIAs for 
anti-HCV antibody detection have high sensitivity and 
specificity because these tests are based on antigens 
in the core, non-structural 3-4-5 proteins of the virus. 
Screening for anti-HCV antibodies by EIA remains a 
simple method, but this type of test is only meaningful 
for ruling out HCV infection in ESRD patients in low-
prevalence settings. In the ESRD patient group, the 
proposed interval for HCV screening via antibody test is 6 
to 12 mo[27]. 
One disadvantage of this serologic test is false-
negative result, which can present challenges for distin-
guishing acute from chronic HCV infection[2]. In a case 
where HCV infection is strongly suspected but the HCV 
antibody EIA is negative, blood testing for HCV RNA 
should be done directly using polymerase chain reaction 
technique[28]. Detection of HCV RNA indicates HCV 
replication. In populations with known higher prevalence 
of HCV infection, a negative EIA result does not rule out 
HCV infection, and testing for HCV RNA is appropriate in 
such cases to avoid missing HCV infections[27]. When EIA 
reveals that an ESRD patient is anti-HCV positive, the 
next step is quantitative determination of viral load. This 
helps confirm the antibody test result and is also useful 
for assessing the patient’s prognostic risk stratification 
prior to antiviral treatment[28]. There are two main 
reasons why blood for HCV RNA testing should be drawn 
prior to a dialysis procedure: (1) presence of heparin in 
the blood sample can lead to false-positive PCR result 
for HCV; and (2) a patient’s HCV RNA level can decrease 
during the HD session (though it will return to baseline 
within 48 h). Adsorption of HCV to dialysis membrane, 
destruction of HCV particles during the HD session, and, 
rarely, escape of HCV into the dialysate are other reasons 
why a patient’s HCV RNA could be falsely low[29].
In addition to detecting HCV RNA, HCV genotyping 
is also required to predict response to treatment and 
to specify the duration and dosage of treatment. HCV 
genotypes 1, 4, 5, and 6 are more resistant to treatment 
and require longer courses of therapy. One study 
identified HCV genotype 1b as the most prevalent subtype 
in patients receiving HD or continuous ambulatory 
peritoneal dialysis in Turkey[1]. In study of Perez et al[30] 
reported findings that HCV genotype 1a was the most 
prevalent subtype in patients receiving HD, with genotype 
1b the next most frequent, followed by genotype 3, 
and other less prevalent genotypes (genotypes 2, 4, 
and 5). This observation may reflect differences in the 
epidemiology of HCV infection, viral characteristics, and 
host factors in ESRD patients[31].
Percutaneous liver biopsy constitutes the most 
reliable tool for examining the effects of HCV infection 
(i.e., stage of liver disease) and ruling out possible other 
concomitant liver diseases[31]. Neither HCV RNA viral 
load nor liver enzymes reflect the severity of liver injury 
decisively[32,33]. Liver enzyme activity and quantity of 
HCV RNA can fluctuate during HCV infection, whereas 
fibrosis is progressive and largely irreversible. There is 
strong evidence that the stage of liver fibrosis during 
HCV infection predicts survival for kidney transplant 
candidates and for renal grafts. In addition, determining 
stage of fibrosis is important for planning the treatment 
of HCV[34]. According to one report, up to 25% of HCV-
infected patients exhibit bridging fibrosis or cirrhosis on 
liver biopsy[31]. Presence of advanced fibrosis does not 
exclude a candidate from KT, but it is inevitable that such 
patients will develop the comorbidities and complications 
of portal hypertension after transplantation[35].
Although liver biopsy is reliable tool, it has significant 
limitations including serious bleeding events, and 
sampling and interpretation errors. Coagulopathy, 
thrombocytopenia, platelet dysfunction, anticoagulation 
during HD and anti-platelet therapy all pose increased 
bleeding risk in ESRD patients or patients on HD. 
In these individuals with increased bleeding risk, a 
transjugular or transfemoral route for liver biopsy may 
be recommended. Note that even when an experienced 
physician performs the biopsy and an experienced 
pathologist interprets the findings, this gold-standard 
technique is associated with up to 20% error in staging 
liver disease[34,35]. Ahmad et al[36] compared the results 
for 46 HD patients with chronic liver disease who 
underwent transjugular liver biopsy and 32 HD patients 
who had undergone percutaneous liver biopsy at the 
same institution. The authors found that both techniques 
obtained adequate specimens for histological diagnosis 
in all patients; however, the complications differed. 
There were no major complications in the transjugular 
liver biopsy group, whereas 12% of the patients in 
the percutaneous liver biopsy developed bleeding 
complications[36]. Some authors have reported the 
progression of HCV-related liver disease in HD patients 
who are on transplantation waiting lists. One study 
concluded that patients whose liver biopsy show Metavir 
fibrosis score 1 or 2 should undergo a repeat liver biopsy 
every 5 years, whereas those with Metavir score 3 
should be followed more intensely, with biopsies every 3 
years[14].
There are also novel non-invasive techniques for 
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risk due to higher incidence of hepatic and non-hepatic 
complications. It is essential that each dialysis center 
carefully follows every HCV-infected ESRD patient 
to determine viral load, do HCV genotyping, assess 
the extent of hepatic fibrosis, and establish optimal 
treatment strategies. A decision tree for the follow-up 
process is shown in Figure 1. Treating HCV infection prior 
to KT helps to prevent post-transplantation complications 
and reduce mortality[3,39-42]. 
There is general agreement that ESRD patients 
with decompensated cirrhosis and portal hypertension 
should be removed from the KT list and referred to the 
liver transplant team to be considered for combined 
liver-KT[43].
It is also generally accepted that every HCV-positive 
ESRD patient who is being evaluated for KT should 
undergo a liver biopsy to assess the stage of liver disease, 
unless there is clear radiological or clinical evidence 
of portal hypertension or decompensated cirrhosis[35]. 
Patients with Metavir fibrosis score ≤ 3 on histologic 
examination should be considered for antiviral treatment. 
Patients with successful sustained viral response (SVR) 
are definite candidates for KT, and those on the waiting 
list should be tested at least annually to confirm the 
durability of the SVR prior to transplantation[35,41,44]. Those 
who have ready living-related donors could be referred 
for KT immediately. There is some largely anecdotal 
evidence that inducing an SVR prior to KT reduces the 
risk of post-transplantation complications. For patients 
who have attained SVR, some authors consider the 
probability of HCV reactivation to be extremely low, 
however, this is controversial, especially when aggressive 
assessing liver fibrosis in ESRD patients with HCV 
infection. Two of these are the aspartate aminotrans-
ferase to-platelet ratio index (APRI) and transient 
elastography (TE) which is performed with a Fibroscan® 
machine. Studies have demonstrated that APRI and TE 
are effective for evaluating hepatic fibrosis in HD patients 
with chronic HCV infection, but both methods have 
some limitations[37,38]. The predictive values and cut-off 
values for these methods as optimized for the healthy 
population may not be valid for ESRD patients[39]. As 
well, the HD procedure and the presence of uremic 
toxins may alter blood levels of apolipoprotein A1 and α-2 
macroglobulin, which can influence Fibroscan® results[37]. 
An APRI score cannot precisely predict the histological 
severity of liver disease, particularly the intermediate 
fibrosis stage[38].
NATURAL COURSE OF HCV IN ESRD 
PATIENTS 
In patients with ESRD, chronic HCV infection usually 
takes an insidious clinical course. Early diagnosis and 
identification of individuals at greater risk for fibrosis 
progression should be the clinician’s main concern. 
Evidence clearly indicates that ESRD patients who 
undergo KT have more favorable results than those who 
do not, and that this also applies for ESRD patients with 
HCV infection. Every ESRD patient should be evaluated 
as a candidate for KT as soon as possible after diagnosis. 
This is important because during the interval between 
diagnosis and transplantation there is increased mortality 
In low-prevalence settings
In high-prevalence settings
Pre-transplantation
Screening and monitoring of HCV infection
Repeat test every 6-12 mo
Test for HCV RNA if high suspicion
Infection control and prevention
Repeat test in local HCV outbreaks 
or if ALT elevated until transplantation 
Anti-HCV
Kidney transplantation
HCV RNA 
-
+
-+Liver biopsy
Consider liver/kidney transplantationAnti-HCV treatment
Mild to moderate fibrosis Cirrhosis, severe fibrosis, 
hepatocellular carcinoma
Figure 1  Decision tree for follow-up of hepatitis C virus-positive end-stage renal disease patients. HCV: Hepatitis C virus; ALT: Alanine aminotransferase.
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immunosuppression is administered[45].
The growing number of ESRD patients with HCV-
related compensated cirrhosis is a major problem. In 
this group, treatment is a dilemma because interferon 
and ribavirin carry potential risk of decompensation 
and serious adverse effects[3,45]. Some authors consider 
these patients “too healthy” for liver transplantation, and 
yet their limited liver reserve, poor nutritional status, 
and increased susceptibility to infections puts these 
individuals at risk for increased perioperative morbidity 
and mortality if they undergo KT[44]. These patients 
require comprehensive and detailed evaluation. Presence 
of portal hypertension should be carefully evaluated to 
decide whether KT alone or combined kidney and liver 
transplantation is appropriate[42,43]. It is recommended 
that patients with wedge hepatic vein pressure > 10 
mmHg may be listed for combined kidney and liver 
transplantation[43]. Some transplantation centers use 
different criteria to make this decision, such as platelet 
count or presence of varices on endoscopy[44]. Making 
the correct treatment decision in these cases in this 
challenging. To improve decision-making in future, 
transplant centers need to report incremental experiences 
and long-term post-transplantation observations.
The other problematic patient group with respect to 
treatment decisions is ESRD patients with HCV who do 
not respond to antiviral treatment or who have been 
assessed as ineligible for antiviral treatment. As HCV 
replication progresses, there is greater risk of accelerated 
liver disease, including hepatic failure and hepatocellular 
carcinoma[46]. KT is not contraindicated for these indivi-
duals, but each such candidate must be informed of all 
difficulties (i.e., those related to progression of HCV and 
restricted antiviral treatment) after transplantation[47]. It 
should also be kept in mind that extending waiting time 
for KT will likely result in poorer liver status for these 
individuals[46,47]. However, any ESRD patient with HCV 
who remains viremic while on a KT waiting list should 
be placed on hold status. These patients should be 
evaluated carefully and frequently to assess HCV disease 
status and their suitability for KT as time on the waiting 
list extended[44]. 
HCV infection after KT 
The natural history of HCV infection after non-liver solid 
organ transplantation is still not fully understood. One 
study revealed that HCV-positive kidney transplant 
recipients had lower survival than HCV-negative 
patients[42]. As noted previously, KT is associated with 
better long-term survival for ESRD patients, even those 
diagnosed with HCV infection. In other words, anti-HCV 
positivity must not preclude HD patients from KT[48].
After KT: Progression and treatment of HCV-related liver 
disease 
Patients with HCV infection who undergo KT can ex-
perience progression of liver disease after the operation. 
This has been identified as the fourth most frequent 
cause of mortality (reported range, 8% to 28%) in long-
term survivors of KT. Increased risk of cardiovascular 
disease, post-transplantation diabetes mellitus, and 
sepsis are considered the primary causes of death after 
KT[49].
A patient’s HCV viral load will increase in the setting 
of immunosuppression, which usually develops within 
the first months after KT[50], but there is no evidence 
that progression of liver disease is correlated with HCV 
RNA load. 
Kamar et al[47] investigated natural course of HCV-
related liver fibrosis after KT. They observed that liver 
biopsy samples from HCV-positive patients after KT 
showed progression of fibrosis in 21 patients, stable 
phase in 21 patients, and regression of fibrosis in 10 
patients. The risk factor most strongly associated with 
progression of hepatic fibrosis was severity of liver 
disease prior to KT[47]. 
In HD patients with HCV who undergo KT, antiviral 
treatment is mandatory after renal transplantation only 
if the individual develops advanced fibrosis or severe 
cholestatic hepatitis. Both these conditions are associated 
with high mortality, and antiviral therapy can be life-
saving[46,51]. For such patients, the decision regarding 
when to provide antiviral therapy should be made 
based on a risk-benefit assessment for each individual 
case[51]. The main concern about interferon (IFN) 
treatment is that it can trigger acute graft rejection[45,46]. 
The optimal approach for antiviral treatment of HCV 
after KT is unclear. A recent meta-analysis by Fabrizi 
et al[52] evaluated 12 clinical trials. In three of these, 
a combination of IFN and ribavirin was used, and the 
estimated rates of SVR and dropout were 18% (95%CI: 
7.0%-29%) and 35% (95%CI: 20%-50%), respectively. 
The most frequent reason for discontinuing the 
combination treatment was graft dysfunction (71.7%). 
There is no evidence that the IFN-ribavirin combination 
is superior to IFN monotherapy[52]. Overall, Fabrizi et al[52] 
agree that treating these patients with anti-viral therapy 
before KT is safer and more effective than administering 
this treatment post-transplantation. 
The risk for acute rejection in HCV-infected patients 
is higher during the first year after KT. In cases where 
anti-viral therapy is necessary after KT, some authors 
recommend waiting at least 1 year after the surgery to 
initiate this treatment[51]. In contrast, other research has 
shown that anti-viral treatment may be more effective 
during the first year after transplantation if the patient 
has stable renal function and no acute rejection occurs[53].
Renal transplant recipients with HCV who have stable 
renal and liver function should be carefully monitored, as 
should those receiving anti-viral therapy. In all cases liver 
function tests should be done every 3 mo and viral load 
should be measured every 6 mo. Liver biopsy should be 
repeated every 3 years[54].
After KT: Immunosuppression in patients with HCV-
related liver disease 
In patients with HCV who undergo KT, immuno-
suppressive therapy is required to prevent rejection of 
Ozer Etik D et al . Hepatitis C in hemodialysis patients
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the renal graft, but this may cause a more rapid and 
aggressive course of HCV infection[55]. In addition to the 
severity and duration of HCV infection, at the time of KT, 
the choice of immunosuppressive drug combination and 
doses can significantly affect the course of HCV infection 
after KT. There is still controversy regarding what 
constitutes the most appropriate immunosuppressive 
combination.
Induction immunosuppressive therapies for kidney 
transplant recipients typically contain T-cell-depleting 
antibodies (OKT3, anti-thymocyte globulin). Induction 
therapies with non-depleting antibodies (i.e., antibodies 
that block interleukin-2) have also been debated. 
There are conflicting reported outcomes regarding the 
hazardous or beneficial effects of these induction immu­
nosuppressive drugs on the course of HCV infection and 
on survival of the renal graft. Earlier studies suggested 
that OKT3 was not a good choice for induction[56], 
whereas a recent report by Roth et al[21] indicated that 
patients who received OKT3 had better liver fibrosis 
scores than those who received daclizumab (an agent 
that binds the interleukin-2 receptors of T-cells). At 
minimum, HCV-infected patients who have undergone 
KT should receive a short course of induction therapy.
Glucocorticosteroids are given in wide range of 
doses to prevent rejection after KT. This treatment is 
associated with increased HCV replication[55]; however, 
Luan et al[57] demonstrated no significant difference 
in mortality between patients who received steroids 
and those who did not. Akalin et al[58] pointed out that 
rapid discontinuation of steroid treatment was not 
associated with worse outcome in HCV-positive renal 
transplant recipients.
Cyclosporin might inhibit HCV replication through 
mediating a blockage of interaction between cyclophilins 
and non-structural protein 5B (HCV-RNA polymerase)[59,60]. 
Kahraman et al[61] investigated kidney recipients with 
HCV, and observed no significant differences between 
a group that received tacrolimus and a group that 
received cyclosporin with respect to viral replication and 
development of hepatic fibrosis.
Mycophenolate mofetil is known to have anti-
viral effects in HCV patients, and acts by inducing the 
expression of anti-viral IFN-related genes[59,62]. In, there 
is no evidence of a specific destructive effect on either 
the renal graft or the HCV infection[55].
There are scarce data on the influence of sirolimus 
and everolimus [both inhibitors of the mammalian target 
of rapamycin (mTOR)] in renal transplant recipients 
with HCV. Luan et al[57] found that mTOR inhibitors were 
associated with 13% increased risk of mortality in this 
patient group. These drugs are not yet recommended 
as standard regimen for renal transplant recipients with 
HCV[55]. 
After KT: Infections
Several studies have confirmed that HCV­positive kidney 
recipients are at increased risk for infections of the central 
nervous system, respiratory system, urinary tract and 
bloodstream[41,63]. Research has identified a significant 
relationship between development of tuberculosis and 
presence of HCV infection in renal transplant recipients[64], 
but it is not clear why HCV-positive recipients are more 
susceptible to this infection. Immunosuppression and 
diabetes are two possible explanations[63].
After KT: HCV-related glomerular disease
HCV infection has been directly linked to glomerular 
disease in both native and transplanted kidneys[65]. 
The most common renal diseases associated with HCV 
infection are membranoproliferative glomerulonephritis 
with or without cryoglobulinemia and membranous 
glomerulonephritis[66]. Meyers et al[65] hypothesized that 
these relationships are explained by increased HCV 
viral load and decreased immunoglobulin synthesis in 
the setting of immunosuppression, and an imbalance 
of antigen and antibody complex status and deposition 
of these complexes in the allograft. Kamar et al[67] 
proposed that these diseases were explained by higher 
cytokine production rather than direct cytotoxic effects 
of HCV on kidney cells. 
After KT: HCV-related new-onset diabetes mellitus
HCV-related new-onset diabetes after KT in patients 
with chronic HCV is an interesting and relatively frequent 
complication[35]. Reported prevalences of this in HCV-
positive and HCV-negative kidney transplant recipients 
are 39.4% and 9.8% respectively[68]. Unfortunately, it 
has been shown that new onset of diabetes after KT 
impairs graft function[69]. The mechanisms proposed for 
HCV-related diabetes mellitus include increased insulin 
resistance, direct cytopathic action of HCV on beta cells, 
and side effects of immunosuppressive drugs[70,71]. 
After KT: HCV-related extrahepatic neoplasia
The role of HCV in the pathogenesis of post-trans-
plantation hematologic malignancies is obvious[72]. Post-
transplant lymphoproliferative disorder was found to 
be significantly more frequent in HCV-positive kidney 
recipients than in HCV-negative kidney recipients[73].
TREATMENT OF HCV INFECTION IN 
PATIENTS WITH ESRD
Carefully treating HCV and achieving SVR prior to KT 
should be primary goals to reduce the likelihood of 
HCV-related complications in the liver and other organs/
systems[74]. Another reason it is important to attain SVR 
before KT relates to the concern that anti-viral therapy 
administered post-transplantation is associated with 
high risk of graft rejection[75]. 
The document entitled Improving Global Outcomes 
recommended that HCV-infected HD patients awaiting 
KT should be treated for HCV, and that attending 
clinicians should decide whether to treat other HCV-
infected patients (i.e., those not on the KT waiting list) 
Ozer Etik D et al . Hepatitis C in hemodialysis patients
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on case-by-case basis. However, HD patients with HCV 
infection rarely receive antiviral therapy[76].
Monotherapy with standard interferon or pegylated 
interferon
Several forms of IFN are available for therapeutic use, 
including α-2a, α-2b, α-n1. In ESRD patients with HCV, 
the recommended administration of IFN ranges from 1-6 
mU as a/daily dose or up to three times weekly. A long-
acting IFN α, namely pegylated IFN (pegIFN), has been 
used safely and effectively for more than a decade. 
Peg IFN α-2a administered at 135 μg weekly and peg 
IFN α-2b administered at 0.5-1 μg/kg are currently 
approved for HCV treatment and are administered 
weekly in stage 3-5 ESRD. Treatment duration is 24 
wk for HCV genotypes 2 or -3 and 48 wk for HCV 
genotypes 1-4[77,78].
Three recently published meta-analyses have 
indicated that SVR, side effects and withdrawal rates in 
patients with ESRD vary according to treatment with 
IFN and pegIFN. 
The meta-analysis by Fabrizi et al[79] evaluated results 
from 645 patients the overall SVR rate was 40%; in the 
subset with HCV genotype 1, the SVR rate was 33% and 
dropout rates were 19% in the group that received IFN 
and 27% in the group that received pegIFN. A typical flu­
like syndrome was the most common side effect. This 
occurred in 41% of patients and required withdrawal of 
anti-viral treatment in 11%. However, the meta-analysis 
by Fabrizi et al[79] was criticized because the studies 
examined were somewhat heterogeneous with regard to 
viral response and dropout rates.
A meta-analysis by Gordon et al[80] in 2008, involved 
546 chronic HD patients with HCV infection who were 
either treated with IFN or pegIFN, with or without 
ribavirin. Only 49 individuals received pegIFN and 
ribavirin. The overall SVR rates were 41% for the IFN 
group (95%CI: 33%-49%) and 37% for the pegIFN 
group (95%CI: 9%-77%). The frequencies of treatment 
discontinuation were 26% for the IFN group (95%CI: 
20%-34%) and 28% for the pegIFN group (95%CI: 
12%-53%). The main side effects were fatigue/weakness 
and loss of appetite. The authors also found that higher 
dose of IFN, lower HCV RNA load prior to treatment, early 
stage of hepatic fibrosis, and HCV genotype other than 
genotype 1 were associated with higher SVR rates[80].
A more recent meta-analysis evaluated data from 
770 HD patients with chronic HCV infection, 491 of 
whom received IFN-alfa2a or IFN-alfa2b and 279 of 
whom received pegIFN-alfa2a or PegIFN-alfa2b. The 
corresponding SVR rates for these two groups were 
39.1% (95%CI: 32.1%-46.1%) and 39.3% (95%CI: 
26.5%-52.1%), and the corresponding dropout rates 
were 22.6% (95%CI: 10.4%-34.8%) and 29.7% 
(95%CI: 21.7%-37.7%). Age younger than 40 years 
was significantly associated with SVR (OR = 2.17; 
95%CI: 1.03-4.50)[81].
Although the above three meta-analyses suggest 
that conventional IFN treatment and pegIFN therapy 
have similar efficacy and safety, many studies have 
shown that pegIFN is superior[27]. For example, one 
study revealed that patients with renal dysfunction who 
were treated with pegIFN had a higher HCV eradication 
rate than HCV patients with normal kidney function 
who received this treatment. This can be attributed to 
decreased renal clearance of pegIFN in the setting of 
ESRD. In practice once weekly dosing of pegIFN is more 
convenient for the patients with renal dysfunction[82].
Combination therapies: Interferon or pegIFN with 
ribavirin 
The combination of pegIFN and ribavirin is considered 
the gold standard therapy for patients with chronic HCV 
who have normal renal function[77]. Some physicians 
are reluctant to use ribavirin in patients with ESRD or in 
those who are on HD due to fear of hemolytic anemia 
which can be exacerbated in the presence of kidney 
dysfunction. Because ribavirin is filtered by the kidneys, 
its clearance is impaired in patients with ESRD, and 
this agent is not removed by dialysis. Despite the fact 
that ribavirin is contraindicated in the setting of renal 
failure, this drug can be used at markedly reduced daily 
doses and with careful monitoring for anemia. Patients 
can be started on a low dose of ribavirin, and doses 
can be increased gradually as long as side effects are 
manageable[82-84]. 
Only a few reports support the combined use of 
pegIFN and ribavirin in ESRD patients or patients on HD 
(Table 1). Rendina et al[88] published the largest series 
to date on the combined use of pegIFN α-2a (135 μg/
wk) plus ribavirin (200 mg daily to every other day) for 
48 wk in 35 HD patients. They observed an SVR rate of 
97% (34 of the/35 patients) and a dropout rate of 14%. 
Only one patient developed severe anemia and had to 
be weaned off treatment. 
The dose of ribavirin should be adjusted based on 
target plasma level which has been identified as 10­15 
mcmol/L in patients with normal kidney function. For 
patients with ESRD, the average dose of ribavirin can 
be 200 mg daily, but some individuals can only tolerate 
200 mg every other day[46]. Assays for monitoring 
plasma ribavirin levels are not routinely available. Even 
when therapeutic ribavirin levels are maintained the 
potential for anemia in HD patients cannot be ruled out. 
Recombinant human erythropoietin or blood transfusions 
can be while maintaining the desired ribavirin dosage, 
for these patients, as these measures can correct 
anemia and improve quality of life during treatment[83]. 
Direct-acting anti-viral agents
Direct-acting anti-viral agents (DAA) have yielded 
exciting results in ESRD patients. When combined with 
IFN and ribavirin, DAA increase SVR rates in patients 
with intact kidney function. However, anemia is an 
important potential side effect of DAA even in patients 
with normal glomerular filtration rate. Further information 
and experience are needed with respect to using DAA-
based therapy in patients with ESRD[89]. More aggressive 
Ozer Etik D et al . Hepatitis C in hemodialysis patients
892 April 28, 2015|Volume 7|Issue 6|WJH|www.wjgnet.com
therapy maybe considered for HD patients who are 
eligible for KT, as HCV eradication prior to transplantation 
can improve outcomes[90].
Two new HCV drugs were approved in 2011: telaprevir 
and boceprevir. Both these are first­wave, first­generation 
NS3-4A protease inhibitors. Two other drug were 
approved in 2013/2014: simeprevir, a second­wave, first­
generation NS3-4A protease inhibitor, and sofosbuvir, a 
nucleotide analogue inhibitor of viral polymerase[91].
Triple therapy for HCV infection currently may have 
several opportunities including a better therapeutic 
schedule in patients with renal failure, which apparently 
do not require dose adjustments to the kidney function, 
yet the detailed data regarding the new drugs in these 
patients are not available[92].
Sofosbuvir and simeprevir are not recommended for 
patients with ESRD or patients who require HD. While 
no dose reduction is necessary when sofosbuvir or 
simeprevir are administered to patients mild to moderate 
HCV infection, a lower dose is needed when this drug 
is administered to patients with severe HCV infection. 
Renal insufficiency has no impact on the pharmacokinetic 
profile of asunaprevir[93]. 
The development of IFN-free or IFN-sparing regimens 
represents a breakthrough in the history of anti-HCV 
treatment. It ıs expected that treatment scenarios for 
chronic HCV patients will change radically in the next 
few years, as safe and potent therapies become more 
accessible. This will simplify the mangement of these 
cases, and will open possibilities to include patient 
populations for which pegIFN is currently contrain-
dicated[94].
In conclusion, HCV infection remains a major 
health problem that can cause substantial liver-related 
morbidity and mortality in patients with ESRD. Various 
forms of IFN with or without ribavirin can be used to 
treat ESRD patients with HCV infection prior to KT; 
however, only approximately one-third of these patients 
will achieve SVR. After an HCV-infected patient has 
undergone KT, IFN-based treatments are generally not 
recommended owing to the high risk of graft rejection. 
Recently introduced IFN- free treatment options are 
promising, but data are lacking regarding their use 
in HD patients with HCV infection. Well-designed 
prospective studies are needed to evaluate the efficacy 
and safety of the new IFN- free regimes in this patient 
group.
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